Key Takeaways:
- Anti-amyloid Alzheimer’s drugs likely provide little or no meaningful clinical benefit, according to a large Cochrane review of 17 studies involving 20,000+ patients.
- The treatments may increase the risk of brain swelling, raising ongoing safety concerns.
- Drugmakers dispute the findings, arguing approved drugs show measurable benefits when evaluated individually.
A new analysis of more than 20,000 patients finds anti-amyloid Alzheimer’s drugs likely offer little clinical benefit while increasing risks such as brain swelling, renewing debate over a treatment strategy pursued for decades.
Review Finds Limited Cognitive Benefit From Alzheimer’s Drugs
A major review released Thursday by nonprofit health research group Cochrane concludes that anti-amyloid Alzheimer’s medicines show “absent or trivial” clinical effects despite years of development and regulatory approvals.
Researchers analyzed 17 placebo-controlled studies covering seven amyloid-beta-targeting monoclonal antibodies, including approved treatments Leqembi and Kisunla, as well as failed drugs such as Aduhelm. The trials collectively enrolled more than 20,000 participants with mild cognitive impairment or mild dementia caused by Alzheimer’s disease.
The analysis found the drugs “probably result in little to no difference” in cognitive function and functional ability compared with placebo groups. Dementia severity also showed minimal change, according to the researchers.
“The effect … on cognitive function and dementia severity at 18 months is trivial,” the research team said in its assessment. Functional improvements were described as “small at best.”
The findings challenge the long-standing theory that removing amyloid plaques from the brain meaningfully slows Alzheimer’s progression. Researchers said successful plaque removal does not appear linked to significant clinical improvement.
The group recommended that future drug development focus on alternative biological mechanisms rather than amyloid targeting alone.
Drugmakers Defend Approved Treatments
Pharmaceutical companies quickly disputed the conclusions, arguing that the review combines successful and unsuccessful therapies into a single analysis.
An Eli Lilly spokesperson said the report relies on “an inherently flawed methodology” by pooling data from drugs that failed clinical trials with medicines that received regulatory approval.
“Combining data on unsuccessful molecules with approved medicines artificially dilutes the observed benefit,” the spokesperson said, adding that individual therapies should be judged on their own evidence.
Leqembi, developed by Biogen and Eisai, received full approval from the U.S. Food and Drug Administration after demonstrating a statistically significant slowing of clinical decline in a placebo-controlled trial. Lilly’s Kisunla also earned full FDA approval based on similar trial outcomes.
Supporters of the anti-amyloid Alzheimer’s drugs say even modest slowing of disease progression can provide meaningful additional time for patients and families facing a degenerative illness with limited treatment options.
Safety Concerns and Long-Running Scientific Debate
Beyond effectiveness, the Cochrane review highlighted safety concerns associated with the drug class. Researchers found a small increase in amyloid-related imaging abnormalities known as ARIA-E, a condition involving brain swelling detectable on MRI scans.
The study found no significant difference in symptomatic swelling cases. Evidence on ARIA-H, a form of brain bleeding, was inconsistent across three studies and could not be pooled into a single conclusion.
The debate comes amid decades of research focused on amyloid beta plaques, once considered the central driver of Alzheimer’s disease. While the approach produced several high-profile drug candidates, many failed late-stage clinical trials.
Confidence in the field was further shaken in 2022 after reports that some influential amyloid research contained fabricated data, intensifying calls for broader scientific exploration.
Despite the controversy, regulators and companies continue to support approved treatments while researchers search for additional disease-modifying therapies.
The Cochrane team said its findings do not end amyloid research but underscore the need for new strategies in the fight against Alzheimer’s disease, which affects millions worldwide and remains without a cure.
